Karyopharm Therapeutics Inc (KPTI)
1.05
-0.04
(-3.67%)
USD |
NASDAQ |
Apr 25, 12:34
Karyopharm Therapeutics Enterprise Value: 104.90M for April 24, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| April 24, 2024 | 104.90M |
| April 23, 2024 | 104.90M |
| April 22, 2024 | 109.50M |
| April 19, 2024 | 114.10M |
| April 18, 2024 | 126.76M |
| April 17, 2024 | 138.27M |
| April 16, 2024 | 106.05M |
| April 15, 2024 | 112.38M |
| April 12, 2024 | 119.86M |
| April 11, 2024 | 133.67M |
| April 10, 2024 | 125.61M |
| April 09, 2024 | 133.67M |
| April 08, 2024 | 134.82M |
| April 05, 2024 | 135.97M |
| April 04, 2024 | 132.52M |
| April 03, 2024 | 127.34M |
| April 02, 2024 | 139.99M |
| April 01, 2024 | 161.28M |
| March 28, 2024 | 153.23M |
| March 27, 2024 | 149.78M |
| March 26, 2024 | 139.42M |
| March 25, 2024 | 139.42M |
| March 22, 2024 | 139.42M |
| March 21, 2024 | 142.87M |
| March 20, 2024 | 140.57M |
| Date | Value |
|---|---|
| March 19, 2024 | 137.12M |
| March 18, 2024 | 148.62M |
| March 15, 2024 | 153.23M |
| March 14, 2024 | 133.67M |
| March 13, 2024 | 142.87M |
| March 12, 2024 | 146.32M |
| March 11, 2024 | 149.78M |
| March 08, 2024 | 160.13M |
| March 07, 2024 | 155.53M |
| March 06, 2024 | 132.52M |
| March 05, 2024 | 122.73M |
| March 04, 2024 | 130.21M |
| March 01, 2024 | 115.83M |
| February 29, 2024 | 112.95M |
| February 28, 2024 | 132.52M |
| February 27, 2024 | 141.72M |
| February 26, 2024 | 130.21M |
| February 23, 2024 | 122.16M |
| February 22, 2024 | 109.33M |
| February 21, 2024 | 118.52M |
| February 20, 2024 | 118.52M |
| February 16, 2024 | 125.42M |
| February 15, 2024 | 128.87M |
| February 14, 2024 | 135.76M |
| February 13, 2024 | 127.14M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
39.79M
Minimum
Nov 29 2023
1.668B
Maximum
Mar 06 2020
539.22M
Average
441.76M
Median
Mar 11 2022
Enterprise Value Benchmarks
| Geron Corp | 1.703B |
| Arbutus Biopharma Corp | 369.48M |
| Verastem Inc | 138.57M |
| Actinium Pharmaceuticals Inc | 130.86M |
| Chimerix Inc | -101.89M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -41.84M |
| Revenue (Quarterly) | 33.75M |
| Total Expenses (Quarterly) | 71.56M |
| EPS Diluted (Quarterly) | -0.36 |
| Gross Profit Margin (Quarterly) | 95.60% |
| Profit Margin (Quarterly) | -124.0% |
| Earnings Yield | -119.0% |
| Normalized Earnings Yield | -118.87 |